Facilitators and barriers to adherence in the initiation phase of disease-modifying antirheumatic drug (DMARD) use in patients with arthritis who recently started their …
A Pasma, A van't Spijker, JJ Luime… - The Journal of …, 2015 - jrheum.org
Objective. To explore themes associated with adherence in the initiation phase for first-time
use of disease-modifying antirheumatic drugs (DMARD) in patients with inflammatory …
use of disease-modifying antirheumatic drugs (DMARD) in patients with inflammatory …
The optimal combination therapy for the treatment of early rheumatoid arthritis
D De Cock, K Van der Elst, S Meyfroidt… - Expert opinion on …, 2015 - Taylor & Francis
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune condition
traditionally viewed as a severe destructive disease affecting physical health and global …
traditionally viewed as a severe destructive disease affecting physical health and global …
Patient experiences with intensive combination-treatment strategies with glucocorticoids for early rheumatoid arthritis
S Meyfroidt, K Van der Elst, D De Cock, J Joly… - Patient education and …, 2015 - Elsevier
Objectives To investigate patients' experiences with intensive combination-treatment
strategies with glucocorticoids (ICTS-GCs) in the early phase of early rheumatoid arthritis …
strategies with glucocorticoids (ICTS-GCs) in the early phase of early rheumatoid arthritis …